Please assess the completion status of the following clinical trial:

Trial Title: Safety of Phenylephrine for Oral Mucositis Prevention

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* cancer patients scheduled to receive at least 5 weeks of radiation therapy to the sub-mandibular lymph nodes~* normal ECG~* normal blood pressure~Exclusion Criteria:~* untreated cardiac disease~* connective tissue disorders~* open sores, wound, ulcerations to oral cavity~* allergy to phenylephrine~* know untreated hypertensin~* abnormal ECG in past 6 months~* taking prescription monoamine oxidase inhibitor (MAOI)~* are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1.25 mg phenylephrine (Type: EXPERIMENTAL): None
- 2.5 mg phenylephrine (Type: EXPERIMENTAL): None
- 5.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 10.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 20.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 40.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 60.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 80.0 mg phenylephrine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).